Skip to main content
Evolva Holding SA logo

Evolva Holding SA — Investor Relations & Filings

Ticker · EVE ISIN · CH1262055788 LEI · 506700IF701J35J34N57 SW Financial and insurance activities
Open in API
Filings indexed 77 across all filing types
Latest filing 2023-08-24 Earnings Release
Country CH Switzerland
Listing SW EVE

About Evolva Holding SA

https://evolva.com/

EvoNext Holdings SA, formerly Evolva Holding SA, is a biotechnology company that researches, develops, and commercializes nature-based ingredients. The company focuses on providing innovative and sustainable solutions for various industries, with primary applications in flavors and fragrances, health ingredients, and nutrition. Its mission is to leverage biotechnology to discover and produce high-quality ingredients for health and wellness markets.

Recent filings

Filing Released Lang Actions
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Earnings Release Classification · 100% confidence The document is explicitly titled as an 'Ad-hoc' announcement released on August 24, 2023, and references 'Half Year Results' and 'Financial highlights 1H 2023'. It provides key financial figures, business updates, and outlook for the first half of the year. This structure—a summary announcement of period-end financial performance that is not the full, comprehensive report (like a 10-K or a full IR)—aligns perfectly with the definition of an Earnings Release (ER). Although it contains detailed tables, the primary function is the initial release of the period's results, often preceding a more detailed Interim Report (IR) or being the primary release for semi-annual results in some jurisdictions. Given the focus on '1H 2023' results and the format of an immediate press release, 'ER' is the most appropriate classification over 'IR' (which is typically a more comprehensive report). It is not a Call Transcript (CT) or an Investor Presentation (IP), but the release itself. H1 2023
2023-08-24 English
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
AGM Information Classification · 98% confidence The document explicitly states that Evolva Holding SA 'convenes extraordinary general meeting (EGM) for 24 August 2023'. It details the agenda items for this meeting, which include proposals regarding capital increases necessary for financing. The document is an 'Ad-hoc' announcement published via a news service (EQS News Service) and references the 'Invitation' to the EGM being published. While it discusses matters related to capital (CAP) and includes a shareholder letter often associated with proxy materials (PSI), the primary, immediate action announced is the convening of a general meeting and the associated proposals. This aligns best with the 'AGM Information' category, as an EGM is a type of general meeting, even though the code is AGM-R (Annual General Meeting - Report/Related Material). Since the core purpose is announcing the meeting and its agenda/materials, AGM-R is the most appropriate fit among the provided options, as it covers materials shared during general meetings.
2023-07-28 English
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
Regulatory Filings Classification · 100% confidence The document is a press release dated July 25, 2023, announcing that Evolva received regulatory approval from the Taiwanese Food and Drug Administration (TFDA) for its Veri-teTM Resveratrol ingredient. This type of announcement, detailing a specific regulatory milestone (approval for use in foods/supplements), is not a comprehensive financial report (like 10-K or IR), nor is it a management change (MANG) or a director's trade (DIRS). It is a specific operational/regulatory update. Since it is not a standard financial filing (10-K, IR, ER, MRQ) and relates to a specific regulatory event, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard regulatory news releases that don't fit the other specific codes (like DVA, DLST, or CAP). It is not an announcement of a report publication (RPA) because it *is* the news itself, not just announcing that a report is available.
2023-07-25 English
Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives
Capital/Financing Update Classification · 95% confidence The document is titled 'Ad-hoc' and is released pursuant to 'Art. 53 LR' (likely a Swiss regulatory requirement for ad-hoc disclosures). The content details a significant corporate event: signing an agreement with a financing partner (Nice & Green) to secure financing until the end of 2023 and continuing the review of strategic alternatives. This type of announcement, concerning financing arrangements and corporate strategy updates outside of routine financial reporting periods (like earnings or annual reports), fits best under 'Capital/Financing Update' (CAP) or potentially a general 'Regulatory Filing' (RNS). Since the core subject is securing CHF 12 million in financing lines and discussing capital structure implications (requiring an EGM for conditional capital), CAP is the most specific fit. It is not an ER, IR, 10-K, or a simple announcement of a report (RPA).
2023-06-26 English
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Capital/Financing Update Classification · 95% confidence The document is explicitly labeled as an 'Ad-hoc' announcement and a 'PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR'. It discusses critical, non-scheduled corporate events: renegotiation of financing, initiation of a review of strategic alternatives, and revocation of guidance. This type of material, which is a material non-public event announcement, typically falls under general regulatory disclosure rules. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate general category for an unscheduled, material regulatory disclosure that doesn't fit elsewhere is 'Regulatory Filings' (RNS). It is not an announcement of a report publication (RPA) because it is the primary disclosure itself, not just an announcement that a report is coming.
2023-06-14 English
Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026
Regulatory Filings Classification · 98% confidence The document is explicitly labeled as 'Ad-hoc' and 'PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR'. It announces a significant business event (signing a multi-year agreement for Vanillin supply) and provides key financial expectations related to this event. This type of immediate, material disclosure, often mandated by stock exchange rules (like Art. 53 LR in Switzerland), is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it contained full period results. Since it is a specific, material business update rather than a full financial report (10-K, IR) or a management discussion (MDA), and it is an immediate announcement, RNS is the most appropriate general regulatory category for non-standard disclosures. It is not a proxy statement (DEF 14A), an investor presentation (IP), or a capital change (CAP). Given the context of immediate, material news disclosure outside of standard periodic reports, RNS is the best fit.
2023-05-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.